0000921895-20-003153.txt : 20201201 0000921895-20-003153.hdr.sgml : 20201201 20201201194550 ACCESSION NUMBER: 0000921895-20-003153 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201127 FILED AS OF DATE: 20201201 DATE AS OF CHANGE: 20201201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Powell David Jonathan CENTRAL INDEX KEY: 0001824493 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 201362106 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 form412566003_12012020.xml OWNERSHIP DOCUMENT X0306 4 2020-11-27 0 0001599298 Summit Therapeutics Inc. SMMT 0001824493 Powell David Jonathan ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2020-11-27 4 M 0 16616 1.92 A 16616 D Common Stock 2020-11-27 4 M 0 12953 1.79 A 29569 D Common Stock 2020-11-27 4 S 0 29569 4.39 D 0 D Common Stock 2020-11-30 4 M 0 13713 1.79 A 13713 D Common Stock 2020-11-30 4 S 0 13713 4.44 D 0 D Stock Option (right to buy) 1.92 2020-11-27 4 X 0 16616 1.92 D 2028-10-19 Common Stock 16616 417639 D Stock Option (right to buy) 1.79 2020-11-27 4 X 0 12953 1.79 D 2029-03-29 Common Stock 12953 404686 D Stock Option (right to buy) 1.79 2020-11-30 4 X 0 13713 1.79 D 2029-03-29 Common Stock 13713 390973 D Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. /s/ Michael Paul Donaldson, Attorney-in-Fact 2020-12-01